Eli Lilly and Company has launched a plan to increase access to quality health care and to improve long-term health for millions of people worldwide –aiming to reach 30 million people in resource-limited areas annually by 2030.
The cornerstone of this goal – known as Lilly 30×30 – is a new five-year, $90 million investment in the Lilly Global Health Partnership, which will improve access to treatment for diabetes, cancer and tuberculosis.
The Lilly Global Health Partnership includes a new $15 million commitment to the Infectious Disease Research Institute (IDRI). This new commitment extends an eight-year collaboration to accelerate early-stage drug discovery and preclinical development for potential new TB medicines.
“In far too many places around the world, a lack of timely diagnosis and access to quality care prevents people and communities from flourishing,” said global health expert Paul Farmer, M.D., Ph.D., who has collaborated with Lilly on fighting TB since the 1990s. “Lilly’s expansive vision for, and significant commitment to, treating TB in poor communities is helping to change that. By strengthening health systems, Lilly’s work not only led to important progress on TB but also laid the groundwork for more integrated care to better diagnose and treat chronic conditions like diabetes and cancer. We are grateful for the company’s vision and commitment, which have improved access to care for current and future generations of patients.”
Company-wide goal to help millions more people
Going well beyond philanthropy, Lilly 30×30 will evaluate many of the company’s current business practices to stimulate thinking for expanding opportunities for medicines to reach more people. To reach 30 million people annually in communities with limited resources – a six-fold increase over the number reached today – Lilly will explore new approaches within different areas of its business, including:
- Initiatives to strengthen health systems and local treatment capacity in communities with significant gaps in care
- Patient education programs
- Collaboration on drug discovery for diseases disproportionately affecting people in resource-limited settings
- Product delivery and packaging more appropriate for people in resource-limited settings
- Innovative business models, including alternative product pricing strategies to improve access to care.
The company will regularly report on the progress toward fulfilling Lilly 30×30 and the specific efforts that contribute to achieving this goal.
Building on a legacy in global health
The Lilly Global Health Partnership and Lilly 30×30 extend and accelerate work done through major global health programs supported by Lilly and the Foundation over the past two decades. These include the Lilly MDR-TB Partnership, which included a decade-long transfer of manufacturing technology for TB medicines, support of early-stage TB drug discovery and improved care in high-burden countries. In 2011, the Lilly NCD Partnership was launched to help governments and key stakeholders improve diabetes prevention and care for people in need. The Lilly Global Health Partnership encompasses and expands these continuing efforts under a single heading.
In addition, Lilly works to improve global health through many other collaborative efforts, including ongoing product donations and funding for Academic Model Providing Access to Healthcare (AMPATH) in Kenya; support of the International Diabetes Federation’s Life for a Child program; and hunger relief efforts.
“Lilly has a strong, 140-year history of improving global health that goes beyond monetary and product donations,” said David A. Ricks, Lilly senior vice president, who will assume the role of Lilly president and chief executive officer on January 1, 2017. “As a research-based company, we bring deep scientific and technical expertise to develop better solutions for people around the world. The Lilly Global Health Partnership will enable us to expand our reach in significant and meaningful ways.”